PROTEINA Co., Ltd. Announces Breakthrough Research Published in Nature Biomedical Engineering
24.7.2024 08:53:00 EEST | Business Wire | Press release
PROTEINA Co., Ltd., in collaboration with Seoul National University (SNU) and Seoul National University Hospital (SNUH), has announced the publication of its latest research in Nature Biomedical Engineering. The study presents a novel approach to personalizing treatment for acute myeloid leukemia (AML) patients by leveraging protein-protein interaction (PPI) profiling to predict drug response.
Critical Need for Personalized AML Treatment
Nearly 90% of AML patients fail to survive without achieving complete remission during initial treatment. ABT-199, in combination with hypomethylating agents, has emerged as a promising therapy by inhibiting the BCL2 protein, a key player in cancer progression. However, varying patient dependency on BCL2 signaling complicates patient selection for this treatment.
Innovative Technique for PPI Profiling
A team of researchers from PROTEINA, SNU, and SNUH tackled this challenge by developing a single-molecule pull-down and co-immunoprecipitation (SMPC) technique. This method quantifies over 20 different types of PPIs and protein expression levels from clinical specimens, using as little as 1 ml of body fluid such as blood or bone marrow aspirate.
The SMPC technique identifies critical PPI links contributing to leukemia cell survival when ABT-199 is administered. The researchers created a prediction model with an AUROC value of 0.94, accurately selecting patients likely to respond to ABT-199 therapy.
Key Findings and Clinical Implications
The study revealed that the BCL2-BAX complex plays a significant role in the survival of AML cells under apoptotic stress induced by ABT-199. Conversely, the BCLxL-BAK complex is linked to resistance, highlighting the drug's selective mechanism.
Through extensive PPI profiling of samples from 32 AML patients, the research identified key PPIs correlating with drug responsiveness. The developed biomarker demonstrated high predictive power, forecasting drug response in 9 out of 10 patients with a sensitivity of 100% and specificity of 83.3%.
Future Directions and Clinical Validation
PROTEINA has acquired venetoclax response prediction technology and patents from SNU and SNUH. The company is currently collaborating with Professor Janghee Woo of Emory University School of Medicine for global clinical validation. "We are thrilled to start this large-scale clinical validation, which is a significant step toward expanding the utility of our platform technology in precision medicine," says Hongwon Lee, Chief Technology Officer at PROTEINA.
Support and Acknowledgements
This research was supported by the National Grants for Leading Scientists of the National Research Foundation of South Korea (NRF) [grant number NRF-2021R1A3B1071354], the Bio Medical Technology Development Program of the NRF [grant number NRF-2018M3A9E2023523], and the Korea Health Technology R&D Project of the Korea Health Industry Development Institute (KHIDI) [grant number HI14C1277].
About PROTEINA Co., Ltd.
PROTEINA Co., Ltd. is a leading biotech company specializing in proteomics, focusing on protein complexes and protein-protein interactions. The company provides cutting-edge analysis services for large pharmaceutical developers, aiming to advance precision medicine through innovative diagnostic technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723842885/en/
Contacts
PROTEINA Co., Ltd.
Jay Chung
Communications Manager
jhchung@proteina.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 15:00:00 EEST | Press release
The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical assessment for age-appropriate design and child safety – helping organizations prioritize children’s values, rights and well-being in their digital products and services. “As AI becomes part of children’s everyday lives, our responsibility as technology leaders has never been greater,” said Mary Ellen Randall, 2026 IEE
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-clinical performance of a selection of linker technology from Debiopharm’s MultiLINK™ Linker Technology suite (MLINK Select, MLINK Duo and MLINK HiSol), revealing positive implications for the development of next generation ADCs and for the future of cancer patients that require more innovative therapies to overcome their disease. Despite remarkable progress in the ADC field, many cancers remain difficult to treat due to biological complexities that challenge current-generation therapies. Tumor heterogeneity can enable cancer cells with low or absent target expression to escape treatment, while acquired resistance to single-payload ADCs may emerge over time and compr
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 15:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-breaking posters at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID 2026) in Maastricht, the Netherlands. Previously shared topline results showed the clinical trial met its primary endpoint, demonstrating pharmacokinetic (PK) comparability between TAK-881 and HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. Secondary analyses showed TAK-881 demonstrated infection outcomes and safety and tolerability profil
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Board of Directors14.10.2026 14:55:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led complex cross-border transactions to strengthen balance sheets, reorganize operations and realign capital structures, both as a primary shareholder and on behalf of independent shareholders. His transa
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 14:21:00 EEST | Press release
EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into the mainland UK, which by 2027 will become its primary EV charging market. The company is building the capital base, technology and operational capability required to deliver reliable
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom